MNPR - Monopar Therapeutics Inc.
| Previous close | 0.9321 |
| Open | 0.9321 |
| Bid | 0.9002 x 2200 |
| Ask | 0.9150 x 800 |
| Day's range | 0.9002 - 0.9450 |
| 52-week range | 0.8110 - 4.8800 |
| Volume | |
| Avg. volume | 278,741 |
| Market cap | 12.065M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable disease WILMETTE, Ill., June 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of c
- GlobeNewswire
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinicalstage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2023 financial results
- GlobeNewswire
Monopar to Present at the Jefferies Radiopharma Innovation Summit
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023Time: 1:00 – 1:30 pm Location: Jefferies Conferenc
- GlobeNewswire
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced completion of a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC). This is a
- GlobeNewswire
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill., March 23, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and
- GlobeNewswire
Monopar to Present at the 35th Annual Roth Conference
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Presentation Details: Date: March 13, 2023Time: 12:30-1:00 pm Pacific Time Location: The R
- GlobeNewswire
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr. Based on promising recently generated preclinical imaging results with MNPR-101-Zr showing high uptake across multiple tumor types, the companies also committed t
- GlobeNewswire
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS): Monopar has opened enrollment for the fifth dose level c
- GlobeNewswire
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it is planning to report over the next two months (1) the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, (2) clinical data from its camsirubicin Phase 1b trial, and (3) a preclinical progress update on its
- GlobeNewswire
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made follow
- GlobeNewswire
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS). The data are displayed in the poster that NUS and Monopar
- GlobeNewswire
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients. The data is displayed in the poster Monopar will be presenting later today at the 2022 Connective Ti
- GlobeNewswire
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 Interim Analysis on Track for Q1 2023Camsirubicin Clinical Data at CTOS 2022 Next WeekMNPR-202 Preclinical Data at ASH 2022 in December WILMETTE, Ill., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2022 financial results and sum
- GlobeNewswire
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023. November 2022: Poster
- GlobeNewswire
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that the abstract on its drug candidate MNPR-202 has been selected for a poster presentation at the 64th ASH Annual Meeting & Exposition (ASH 2022). ASH 2022, being held in New Orleans, is the premier event in malignant and no
- GlobeNewswire
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its abstract on camsirubicin submitted to the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting has been selected for a poster presentation. CTOS 2022, held in Vancouver, Canada, brings together the world’s le
- GlobeNewswire
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Interim Analysis Planned for Q1 2023WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced an update on its actively enrolling Validive Phase 2b/3 VOICE clinical trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngea
- GlobeNewswire
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference. Presentation Details: Date: October 6, 2022Time: 12:00 p.m. (ET)Location: The Yale Club, N
- GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 Camsirubicin Phase 1b Dose-Escalation Trial Now Dosing 4th LevelWILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, tod
